PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 883-894

  Jani, Jitesh P ^a   Arcari, Joel ^b   Bernardo, Vincent ^b   Bhattacharya, Samit K ^b   Briere, David ^a   Cohen, Bruce D ^b   Coleman, Kevin ^b   Christensen, James G ^a   Emerson, Erling O ^b   Jakowski, Amy ^b   Hook, Kenneth ^a   Los, Gerrit ^a   Moyer, James D ^b   Pruimboom Brees, Ingrid ^b   Pustilnik, Leslie ^b   Rossi, Ann Marie ^b   Steyn, Stefan J ^b   Su, Chunyan ^b   Tsaparikos, Konstantinos ^a   Wishka, Donn ^b   Yoon, Kwanslk ^b   Jakubczak, John L ^a,c,d   more..

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; DOCETAXEL; PF 03814735; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINESIS; DRUG BIOAVAILABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTINUCLEAR CELL; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; TUMOR GROWTH;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HISTONES; HUMANS; MICE; MICE, NUDE; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950821678     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0915     Document Type: Article

References (31)

1. Carmena M, Earnshaw WC. The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-854
2. Bischoff JR, Plowman GD. The Aurora/lp11p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999;9:454-459
3. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev MoI Cell Biol 2001;2:21-32.
4. Marumoto T, Honda S, Hara T, et al. Aurora A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278:51786-51795
5. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drasophila aurora kinase is oncogenic and amplified in human colorectal cancer. EMBO J 1998;17:3052-3065
6. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10.
7. Ota T, Suto S, Katayama H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002;62: 5168-5177
8. Sen S, Zhou H, Zhang RD, et al. Amplificatlon/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-1329
9. Zhu J, Abbruzzese JL, Izzo J, Hittelman WN, Donghul L. AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet Cytogenet 2005; 159:10-17
10. Gritsko TM, Coppola D, Picaga JE, et al. Activation and overexpression of centrosome kinase BTAK/Aurora A, in human ovarian cancer. Clin Cancer Res 2003;9:1420-1426
11. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 2001; 61:2212-2219
12. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10:2065-2071
13. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/ BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-193
14. Kimura M, Matsuda Y, Yoshloka T, Okano Y. Cell Cycle-dependent expression and centrasomal localization of a third human Aurora/ IPH -related protein kinase, AIK3. J Biol Chem 1999;274:7334-7340
15. Takahashi T, Futamura M, Yoshimi N, et al. Centrasomal kinases, HsAIRk1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 2000;91:1007-1014
16. Gautschi O, Heighway J, Mack PC, Pumell PR, Lara PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1639-1648
17. Ikezoe T. Aurora kinases as an anti-cancer target. Cancer Lett 2008; 262:1-9.
18. Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A Kinase. Proc Natl Acad Sci U S A 2007;104:4106-4111
19. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-267
20. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro Gl. The aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53 dependent postmitotic checkpoint function. Cancer Res 2006;66: 7668-7677
21. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-3168
22. VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucinl RV. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 2009;8:930-939
23. Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by iducing apoptosis. Clin Cancer Res 2007;13:3682-3688
24. Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-388
25. Arcari J, Bhattacharya S, Brosius A, et al. Pyrimidine derivatives for the treatment of abnormal cell growth and their preparation. PCT Int Appl WO 2007072158 A2 2007.
26. Roberts WG, Ung E, Whalen P, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008;68:1935-1944.
27. Jani JP, Finn RS, Campbell M, et al. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer Res 2007;67:9887-9893
28. Carpinelli P, Moll J. Is there a future for Aurora kinase inhibitors for anticancer therapy? Curr Opin Drug Discov Devel 2009;12:533-542
29. Prigent C, Glover DM, Giet R. Drosophila Nek2 protein kinase knockdown leads to centrosome maturation defects while overexpression causes centrosome fragmentation and cytokinesis failure. Exp Cell Res 2005;303:1-13.
30. Vassilev LT, Tovar C, Chen S, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA2006;103:10660-10665
31. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992;257: 1955-1957